Beryl Drugs Ltd.

BSE: BERLDRG524606ISIN INE415H01017

Healthcare
Pharmaceuticals

BSE listing

Share price

₹23.69+0.48 (+2.07%)

as of 18 Sep 2026

52W high: ₹27.60
52W low: ₹15.92
Off 52W high: -14.17%
1M return: +6.95%
3M return: +6.04%
6M return: +10.70%
1Y return: +0.51%
20D avg volume: 1,965
50 DMA: ₹22.85
200 DMA: ₹22.17

Key ratios Standalone

Market cap: ₹12.01 Cr
Current price: ₹23.69
52W high / low: ₹27.60 / ₹15.92
Face value: ₹10.00
P/E: 19.26
P/B: 1.29
EPS (TTM): ₹1.23
Book value / share: ₹18.36
ROE: 6.72%
ROCE: 8.90%
Operating margin: 8.88%
Net margin: 3.03%
Debt / equity: 0.24
Net debt: ₹2.12 Cr
Interest cover: 2.74
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 73.5 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q4 FY24
Income statement
	7.30	5.13	3.78	5.12	4.79	3.97	—
	0.27	0.34	0.07	0.04	0.04	1.25	—
	7.30	4.60	4.46	4.90	4.77	5.12	—
	4.34	3.43	2.08	2.79	2.21	2.46	—
	0.00	0.00	0.00	0.00	0.00	0.00	—
	0.63	0.63	0.79	0.58	0.53	0.59	—
	0.06	0.07	0.09	0.08	0.10	0.08	—
	0.32	0.40	0.32	0.39	0.38	0.32	—
	1.86	0.38	1.22	1.27	1.73	1.31	—
	0.27	0.87	-0.61	0.26	0.07	0.10	—
	0.00	0.00	0.00	0.00	0.00	0.00	—
	0.27	0.87	-0.61	0.26	0.07	0.10	—
	0.05	0.30	-0.44	0.25	0.05	-0.05	—
	0.22	0.56	-0.17	0.01	0.02	0.15	—
	0.44	1.11	-0.33	0.02	0.04	0.30	—
Key metrics
	0.65	1.34	-0.20	0.73	0.55	0.50	—
	8.90%	26.10%	-5.30%	14.30%	11.50%	12.60%	—
	3.00%	10.90%	-4.50%	0.20%	0.40%	3.80%	—
	—	9.00%	—	2.90%	—	1.50%	—
	52.40%	29.20%	—	—	—	—	—
	1,000.00%	273.30%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	21.33	18.82	21.15	—
	0.72	0.49	1.41	—
	21.26	18.72	21.69	—
	12.64	10.51	11.12	—
	0.00	0.00	0.00	—
	2.63	2.53	2.21	—
	0.30	0.34	0.53	—
	1.43	1.49	1.25	—
	4.73	4.59	6.92	—
	0.79	0.59	0.87	—
	0.00	0.00	0.00	—
	0.79	0.59	0.87	—
	0.16	0.16	0.29	—
	0.62	0.42	0.58	—
	1.24	0.30	1.14	—
Key metrics
	2.52	2.42	2.65	—
	11.81%	12.90%	12.50%	—
	2.91%	2.20%	2.70%	—
	—	8.90%	12.00%	—
	—	-11.00%	—	—
	—	-27.60%	—	—
	—	-0.17	0.45	—
	—	8.69	4.55	—
	—	0.24	0.43	—
	—	2.12	3.27	—
	—	73.5	107.7	—
Balance sheet
	—	14.96	15.96	—
	—	7.03	9.04	—
	—	0.27	0.81	—
	—	2.09	5.46	—
	—	3.13	1.90	—
	—	1.14	0.74	—
	—	6.82	6.00	—
	—	1.43	1.12	—
	—	4.53	4.30	—
	—	2.39	4.08	—
	—	2.39	2.34	—
	—	0.00	1.74	—
	—	9.89	9.50	—
Cash flow
	—	3.65	2.64	—
	—	-2.16	-0.40	—
	—	-2.03	-1.55	—
	—	3.82	2.19	—

Compounded growth

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 27.81%

Holder	Type	Holding	Previous	Change
SANJAY SETHI	Promoter	10.88%	—	—
SUDHIR SETHI	Promoter	10.08%	—	—
SANGITA SETHI	Promoter	3.78%	—	—
PRADEEP KUMAR JAIN	Public	3.52%	—	—
SONIYA SETHI	Promoter	3.07%	—	—
MAYANK SIYAL	Public	2.07%	—	—
SAMIR NARENDRA GUPTA	Public	1.77%	—	—
JINESH JOSEPH	Public	1.67%	—	—
PUNJABHAI KESHAVBHAI JADEJA	Public	1.23%	—	—
RAM BABU VIJAY	Public	1.19%	—	—
SIMIMON KALLUPURACKAL JOBY	Public	1.05%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

NEWSPAPER PUBLICATION OF 33RD ANNUAL GENERAL MEETING NOTICE6 Sep 2026 · Company Update / Newspaper Publication
ANNUAL REPORT 2025-20263 Sep 2026 · Others / Reg. 34 (1) Annual Report
33RD ANNUAL GENERAL MEETING NOTICE3 Sep 2026 · AGM/EGM / AGM
EVOTING DATES FOR THE PURPOSE OF 33RD ANNUAL GENERAL MEETING3 Sep 2026 · Company Update / General
RECORD DATE3 Sep 2026 · Corp. Action / Record Date
INTIMATION OF ANNUAL BOOK CLOSURE2 Sep 2026 · Corp. Action / Book Closure
OUTCOME OF BOARD MEETING2 Sep 2026 · Board Meeting / Outcome of Board Meeting
Beryl Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/09/2026 ,inter alia, to consider and approve approve board report and other ....27 Aug 2026 · Board Meeting / Board Meeting
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir Sethi20 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir Sethi19 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
NEWSPAPER PUBLICATION OF UNAUDITED QUARTERLY FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 202613 Aug 2026 · Company Update / Newspaper Publication
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 202611 Aug 2026 · Result / Financial Results
OUTCOME OF BOARD MEETING11 Aug 2026 · Board Meeting / Outcome of Board Meeting
Beryl Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve the unaudited financial results ....5 Aug 2026 · Board Meeting / Board Meeting
TEMPORARY UNAVAILABILITY OF THE COMPANY''S WEBSITE "www.beryldrugs.com" DUE TO AN UNEXPECTED TECHNICAL ISSUE.21 Jul 2026 · Company Update / General
CERTIFICATE UNDER REGULATION 74(5) OF SEBI (DP) REGULATIONS, 20186 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
NON-APPLOCABILITY CERTIFICATE UNDER REGULATION 57(5) FOR THE QUARTER ENDED 30TH JUNE, 20266 Jul 2026 · Others / 57 (5) : intimation after the end of quarter
CLOSURE OF TRADING WINDOW FOR THE QUARTER ENDED 30.06.202630 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir Sethi29 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
CHANGE IN REGISTERED OFFICE OF THE COMPANY FROM 133, KANCHAN BAGH, INDORE TO 29, NEER NAGAR, MAYANK WATER PARK ROAD, BICHOLI, INDORE WITHIN LOCAL LIMITS OF SAME CITY16 Jun 2026 · Company Update / Change in Registered Office Address
OUTCOME OF BOARD MEETING16 Jun 2026 · Board Meeting / Outcome of Board Meeting
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir Sethi12 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir Sethi11 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir Sethi10 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Beryl Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/06/2026 ,inter alia, to consider and approve change in registered office of ....8 Jun 2026 · Board Meeting / Board Meeting
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir Sethi8 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
NEWSPAPER PUBLICATION OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 202629 May 2026 · Company Update / Newspaper Publication
AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 202628 May 2026 · Result / Financial Results
OUTCOME OF BOARD MEETING28 May 2026 · Board Meeting / Outcome of Board Meeting
Beryl Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve consider and approve the Audited ....20 May 2026 · Board Meeting / Board Meeting
PROCEEDINGS OF EGM13 May 2026 · AGM/EGM / EGM
VOTING RESULTS OF EGM HELD ON 11.05.202612 May 2026 · AGM/EGM / EGM
SCRUTINIZERS REPORT FOR THE EGM HELD ON 11TH MAY 202512 May 2026 · AGM/EGM / EGM
RELATED PARTY TRANSACTION(S) WITH AMINOVA INFUSIONS PVT LTD11 May 2026 · Company Update / General
REGULARISATION OF APPOINTMENT OF MRS. NEHA SARDA AS INDEPENDENT DIRECTOR OF THE COMPANY11 May 2026 · Company Update / General
APPOINTMENT OF MRS. NEHA SARDA AS NON EXECUTIVE INDEPENDENT DIRECTOR OF THE COMPANY11 May 2026 · Company Update / Change in Management
REGULARISATION OF APPOINTMENT OF MR. SHALENDRA PATHAK AFTER THE APPROVAL FROM SHAREHOLDERS AS WHOLE TIME DIRECTOR OF THE COMPANY IN THE EGM HELD ON 11.05.202611 May 2026 · Company Update / Change in Management
OUTCOME OF EXTRA-ORDINARY GENERAL MEETING OF THE COMPANY11 May 2026 · AGM/EGM / EGM
NON- APPLICABILITY CERTIFICATE FOR THE YEAR ENDED 31st MARCH 202613 Apr 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....8 Apr 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

Board meetings

11 Aug 2026 Board Meeting - Financial Results